Founder And Cso
CurrentLupagen is enabling bedside cell therapy by creating a closed loop autologous cell modification system lowering costs and increasing patient safety and convenience.
2017 - Present
~9 yrs 6 mos
AeroLeads people directory · profile
David Peritt Email & Phone Number
Enabling In-Situ Generation of Therapeutic Cells
at
Lupagen
1 work email found
@pfizer.com
2 phones found area 224
LinkedIn matched
✓ Verified Jul 2026
4 data sources
Profile completeness 100%
Current company
Role
Enabling In-Situ Generation of Therapeutic Cells
Location
Greater Chicago Area, United States
Who is David Peritt? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
David Peritt is listed as Enabling In-Situ Generation of Therapeutic Cells at Lupagen, based in Greater Chicago Area, United States. AeroLeads shows a work email signal at pfizer.com, phone signal with area code 224, and a matched LinkedIn profile for David Peritt.
David Peritt previously worked as Founder and CSO at Lupagen and Adjunct Professor at Northwestern University. David Peritt holds Doctor Of Philosophy (Ph.D.), Immunology from University Of Pennsylvania.
Company email context
Email format at Lupagen
This section adds company-level context without repeating David Peritt's masked contact details.
{first}.{last}@pfizer.com
86% confidence
AeroLeads found 1 current-domain work email signal for David Peritt. Compare company email patterns before reaching out.
Profile bio
About David Peritt
Compared to traditional cell therapy such as CAR-T, in vivo Gene Therapy creates a simple drug model that is not encumbered by cell therapy manufacturing limitations. The ability to genetically modify (gene therapy) immune cells in the body will significantly lower cost, complexity and increase safety thus broadening access in oncology and expanding gene therapy into many more indications. However, the ability to deliver genetic payloads specifically to immune cells with minimal off target impact (safety) and with the ability to redose (efficacy) remain significant challenges and limit the huge potential of gene therapy for the creation of therapeutic cells. Lupagen has created a delivery device to address these challenges. At the bedside, peripheral blood immune cells are removed for a short time, incubated with the gene delivery vehicle and returned to the patient in a closed loop extracorporeal system similar to dialysis or plasmapheresis. Lupagen partners with biopharma companies to develop their in vivo gene therapy programs by supplying extracorporeal delivery systems for preclinical and clinical studies. In the US this is regulated as a combination product similar to an auto-syringe where the biopharma company maintains full control over their product. Lupagen simply supplies the devices and disposables required for clinical testing and into commercialization. The cost saving compared to cell therapy manufacturing is immense.
Listed skills include Immunology, Biotechnology, Cell, Antibodies, and 22 others.
Current workplace
David Peritt's current company
Company context helps verify the profile and gives searchers a useful next step.
17 roles · 42 years
David Peritt work experience
A career timeline built from the work history available for this profile.
Adjunct Professor
CurrentMcCORMICK SCHOOL OF ENGINEERING. Industry advisory board, guest lecturer, co-op student advisor and curricula advisor for masters of biotechnology program.
Apr 2015 - Present
Science & Technology Committee Member
Current
2015 - Present
~11 yrs 6 mos
Scientific Advisory Board Member
Current
2021 - Present
~5 yrs 6 mos
Consultant
Current
2021 - Present
~5 yrs 6 mos
Chief Scientific Officer
Sigilon Therapeutics, Inc.
Gene modified allogeneic cell therapy for the delivery of therapeutic proteins implanted in an immune evading system. Built scientific team that in 2020 obtained IND/CTA clearance, first in human studies initiated, raised capital and took public on Nasdaq (SGTX).
Jun 2017 - Apr 2021
Program Lead, Tolerance And Cell Therapy
Research Program Lead for CAR-Tregs to move the patient experience from therapeutic to durable or curative responses for autoimmune diseases.
Feb 2016 - May 2017
Biosimilars Biology And Immunology
Oversaw early biosimilar pipeline strategy, responsible for immunogenicity leading to FDA and EMA approvals for Retacrit, Inflectra, Nivestim and Nyvepria.
2012 - 2015
~3 yrs
Strategic Corporate Investor, Cell Therapy And Regenerative Medicine
Responsible for identifying, evaluating and championing strategic investments, acquisition and late stage development in the areas of regenerative medicine, oncology and hematology. Investments included Fate Therapeutics, Kiadis and ViaCyte.
Jul 2008 - Nov 2011
Director
Immune Cell Therapy Diligence Creating strategy and recommendations for J&J pharmaceutical division to coordinate cell therapies across organization.Co-founder, Immune Cell Therapy Incubator co-founded internal JNJ venture company to develop autologous regulatory T cell therapy for the treatment of immune mediated diseases. Responsible for business development, intellectual property, in-licensing and building research team of ~25.
2005 - 2008
~3 yrs
Head Of Research And Development
Therakos
Chief scientist and member of management team at Therakos. Led and managed research teams for the development of novel autologous cell therapies and team focused on improvements and clinical trials to expand indications for bedside cell therapy, photopheresis.
Jun 2001 - Jun 2007
Senior Research Scientist
Assisted in launch of infliximab - Remicade, the first marketed anti-TNF therapeutic with $10B+ in sales.Managed a unit responsible for the development of therapeutic antibodies including siltuximab - Sylvant (anti IL-6) and ustekinumab - Stelara (anti IL-12/23).
1998 - 2001
~3 yrs
Graduate School
In the laboratory of Giorgio Trinchieri discovered NK1 and NK2 subsets, novel roles for IL-12 in driving IL-10 production and further characterized the CD244 receptor and its role as an HIV predictive marker for disease progression.
1992 - 1998
~6 yrs
Associate Scientist
Responsible for characterization of a novel IL-1 antagonist and determination of its viability as a therapeutic for the company.
1991 - 1992
~1 yr
Graduate Student
Helped identify biological activity and characterization for a novel IL-1 inhibitor.
1988 - 1991
~3 yrs
Scientist
Conducted research to understand the immunosuppressive properties of ethanol abuse.
1986 - 1987
~1 yr
Research Intern
Assessed rare metal nutritional content for foods to be incorporated into the Handbook 8.
1985 - 1985
3 education records
David Peritt education
Doctor Of Philosophy (Ph.D.), Immunology
University Of Pennsylvania
Master Of Science (Msc), Immunology
The Hebrew University Of Jerusalem
Bachelor Of Science (B.Sc.), Science
University Of Maryland
FAQ
Frequently asked questions about David Peritt
Quick answers generated from the profile data available on this page.
What company does David Peritt work for?
David Peritt works for Lupagen.
What is David Peritt's role at Lupagen?
David Peritt is listed as Enabling In-Situ Generation of Therapeutic Cells at Lupagen.
What is David Peritt's email address?
AeroLeads has found 1 work email signal at @pfizer.com for David Peritt at Lupagen.
What is David Peritt's phone number?
AeroLeads has found 2 phone signal(s) with area code 224 for David Peritt at Lupagen.
Where is David Peritt based?
David Peritt is based in Greater Chicago Area, United States while working with Lupagen.
What companies has David Peritt worked for?
David Peritt has worked for Lupagen, Northwestern University, Alliance For Regenerative Medicine, Korro Bio, Inc., and Guidepoint.
How can I contact David Peritt?
You can use AeroLeads to view verified contact signals for David Peritt at Lupagen, including work email, phone, and LinkedIn data when available.
What schools did David Peritt attend?
David Peritt holds Doctor Of Philosophy (Ph.D.), Immunology from University Of Pennsylvania.
What skills is David Peritt known for?
David Peritt is listed with skills including Immunology, Biotechnology, Cell, Antibodies, R&D, Medical Devices, Biopharmaceuticals, and Life Sciences.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial